IGXT Stock UPDATES Intelgenx Technologs (IGXT) 0.5210 08/30/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Intelgenx Technologs (IGXT) 0.5210 $IGXT

IntelGenx to Present at the Rodman & Renshaw Global Investment Conference
GlobeNewswire - Thu Aug 21, 1:18PM CDT
IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) ("IntelGenx" today announced that Dr. Horst Zerbe, Chairman, President and Chief Executive Officer, will present at the Rodman & Renshaw Global Investment Conference to be held September 9, 2014 at 9:35 a.m. Eastern Time.

H.C. Wainwright Initiates Coverage of Pacific Therapeutics Partner Intelgenx with a Buy Recommendation
ACCESSWIRE - Fri Aug 15, 7:48AM CDT
VANCOUVER, BC, Canada / ACCESSWIRE / August 15, 2014 / Pacific Therapeutics Ltd. (CSE: PT) (OTC Markets: PCFTF) (Frankfurt: 1P3) (the "Company" is a clinical stage specialty pharmaceutical company focused on the repurposing and reformulation of existing FDA approved drugs for large markets. The Company's lead programs focus on diseases of excessive scarring (fibrosis) and erectile dysfunction which are $1 billion plus market opportunities.

IntelGenx Reports Q2, 2014 Results and Provides Corporate Development Update
GlobeNewswire - Thu Aug 07, 8:31AM CDT
IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) ("IntelGenx" today announced financial results for the three and six months ended June 30, 2014 and provided an update on corporate developments. All amounts are in U.S. Dollars, unless otherwise stated.

IntelGenx to Host Management Call
GlobeNewswire - Fri Jul 18, 11:38AM CDT
IntelGenx Technologies Corp. (TSX-V:IGX) (OTCQX:IGXT) ("IntelGenx" today announced that its interim CEO, Dr. Horst G. Zerbe, will be hosting a conference call on July 23rd, 2014 at 10:00 AM Eastern Time.

IntelGenx Announces Management Changes
GlobeNewswire - Wed Jul 16, 3:52AM CDT
IntelGenx Technologies Corp. (TSX-V:IGX) (OTCQX:IGXT) ("IntelGenx" announced today that the board of directors (the "Board" of IntelGenx has accepted, with immediate effect, the resignation of Dr. Rajiv Khosla as President and Chief Executive Officer ("CEO" of IntelGenx and as a member of the Board.

IntelGenx Announces Equity Analyst Coverage by H.C. Wainwright
GlobeNewswire - Tue Jul 01, 7:11AM CDT
IntelGenx Technologies Corp. (TSX-V:IGX) (OTCQX:IGXT) ("IntelGenx" today announced that H.C. Wainwright has initiated equity analyst coverage of IntelGenx.

IntelGenx Reports 2013 Annual Results and Provides Corporate Development Update
GlobeNewswire - Tue Mar 11, 7:32AM CDT
IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) (the "Company" today announced financial results for its fiscal year ended December 31, 2013 and provided an update on operational developments. All amounts are in U.S. Dollars, unless otherwise stated.

IntelGenx and RedHill Biopharma Submit Response to FDA CRL for VersaFilm(TM) Product for Migraines
GlobeNewswire - Mon Mar 03, 7:05AM CST
IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) ("IntelGenx" , a Canadian drug delivery company focusing on oral drug delivery, today announced, together with RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) ("RedHill" , an emerging Israeli biopharmaceutical company focused primarily on the development and acquisition of late clinical-stage drugs, that they submitted a response to the Complete Response Letter ("CRL" of the U.S. Food and Drug Administration ("FDA" for the New Drug Application ("NDA" for their VersaFilm(TM) Oral Film Product for the treatment of acute migraines.

RedHill Biopharma and IntelGenx Submit Response to FDA CRL for RHB-103 Migraine Oral-Film
GlobeNewswire - Mon Mar 03, 7:00AM CST
RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) ("RedHill" , an emerging Israeli biopharmaceutical company focused primarily on the development and acquisition of late clinical-stage drugs, today announced, together with IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) ("IntelGenx" , a Canadian drug delivery company focusing on oral drug delivery, that they submitted a response to the Complete Response Letter ("CRL" of the U.S. Food and Drug Administration ("FDA" for the New Drug Application ("NDA" for RHB-103, an oral thin-film rizatriptan for the treatment of acute migraines.

IntelGenx Announces Receipt of Two Additional U.S. Patent Allowances Related to Proprietary Technology
GlobeNewswire - Wed Feb 26, 7:42AM CST
IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) ("IntelGenx" , a Canadian drug delivery company focusing on oral drug delivery, today announced that it has received a Notice of Allowance ("NOA" from the United States Patent and Trademark Office for U.S. Patent Application Serial No. 11/647,033 entitled "Multilayer tablet" which covers the technology used in our hypertension product currently under development. A second NOA has been received for U.S. Patent Application Serial No. 11/782,838 entitled "Controlled-release pharmaceutical tablets" which is related to the drug delivery technology used in Forfivo XL(R), IntelGenx' first FDA-approved product currently commercialized in the U.S. These two NOA's conclude the examination of each U.S. patent application and will result in the issuance of two U.S. patents after administrative processes are completed.

IntelGenx Achieves Positive Bioequivalence Results for Erectile Dysfunction VersaFilm(TM) Tadalafil Product
GlobeNewswire - Mon Feb 24, 7:08AM CST
IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) ("IntelGenx" , a Canadian drug delivery company focusing on oral drug delivery, today announced the completion of a pilot biostudy with its proprietary VersaFilm(TM) tadalafil product for erectile dysfunction that indicated bioequivalence with the leading brand reference listed drug (RLD) tadalafil product.

IntelGenx Technologies Report Delivers Analyst Opinion and Fundamental Data
PR Newswire - Wed Feb 05, 6:00AM CST
NEW YORK, Feb. 5, 2014 /PRNewswire - IntelGenx Technologies Corp (OTC: IGXT), is a drug delivery company, that engages in the development of novel oral immediate-release and controlled-release products for the pharmaceutical market.

IntelGenx and RedHill Biopharma Receive Complete Response Letter From FDA for VersaFilm(TM) Oral Film Product for Acute Migraines
GlobeNewswire - Tue Feb 04, 9:49PM CST
-- FDA's letter accepted the bioequivalence study and safety information submitted and requires no additional clinical studies; IntelGenx and RedHill plan to address remaining issues, primarily related to third party manufacturing, packaging and labeling, within weeks based on available data

11th Trust Dialogue - Impunity Number One Enemy of Democracy-Ekeweremadu
by Ronald Mutum - All Africa Global Media - Fri Jan 17, 1:21AM CST
The Deputy Senate President, Ike Ekeweremadu has said impunity in politics is the number one enemy of Nigeria's democracy.

IntelGenx Announces Additional Development and Commercialization Agreement With Par Pharmaceutical, Inc. for Two More Products
GlobeNewswire - Mon Jan 13, 7:05AM CST
IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) ("IntelGenx" or the "Company" , a Canadian drug delivery company focusing on oral drug delivery, today announced that it has entered into another development and commercialization agreement with Par Pharmaceutical, Inc. ("Par" for two new products utilizing IntelGenx' proprietary oral drug delivery platforms.

IntelGenx Grants Stock Options
GlobeNewswire - Thu Jan 09, 10:34AM CST
IntelGenx Technologies Corp. ("IntelGenx", or the "Company" (TSX-V:IGX) (OTCQX:IGXT) announced today that the Company's board of directors granted options to acquire 120,000 common shares under the 2006 Stock Option Plan, as amended. The options were granted to the President and Chief Executive Officer, Dr. Rajiv Khosla in accordance with his employment agreement.

IntelGenx Closes $3.5 Million Public Offering
GlobeNewswire - Mon Dec 16, 2:35PM CST
IntelGenx Technologies Corp. (OTCQX:IGXT) (TSX-V:IGX) ("IntelGenx" , a drug delivery company focused on the development of novel oral rapidly disintegrating delivery systems including its proprietary VersaFilm(TM) technology, as well as oral controlled-release products, announced today that it has closed a registered public offering to raise gross proceeds of approximately $3.5 million.




Scroll down for more posts ▼

Top 10 Most Recent News Articles

PPL's January Dividend Keeps Utility Appeal Intact

Updated Category News Views 50

A dividend notice is rarely thrilling, but it can still separate a steady utility from a story stock peddling fumes. PPL Corporation declared a quarterly common dividend of $0.2850 per share on Nov. 20, payable Jan. 4, 2027. Shareholders must be on the books by Dec. 10, 2026, to receive it. Plain vanilla stuff, yes. Still, plain vanilla is often precisely why utility...

Continue Reading
Label-Free Detection Has a Solid, Narrow Growth Lane

Updated Category News Views 20

Biologics labs are turning into a far better hunting ground for analytical equipment than the old, broad-brush research story suggests. Label-free detection is not a giant market, and nobody should dress it up as one. But the projected move from $0.58 billion in 2026 to $0.85 billion by 2031 points to a useful 8.1% annual growth lane, driven by work researchers genuinely...

Continue Reading
Stowers Brings a Transformation CTO Into Its Lab

Updated Category News Views 125

Data Has Become Lab Infrastructure Microscopes may get the glory, but the plumbing behind modern biology is increasingly digital, sprawling and unforgiving. That is why Stowers Institute for Medical Research appointing Brandon Mayer as vice president and chief technology officer on November 19, 2026, deserves more attention than the usual executive-shuffle treatment. This...

Continue Reading
Intel Investors Face January 12 Lead Plaintiff Deadline

Updated Category News Views 178

A Narrow Calendar Window Has Opened Intel holders have another legal deadline to put on the fridge, and this one is not a casual housekeeping item. A securities class action has been filed in the Northern District of California on behalf of investors who bought or acquired Intel shares between July 23, 2026, and October 29, 2026. The deadline to seek appointment as lead...

Continue Reading
FAA Funding Gridlock Raises Aviation Reliability Risk

Updated Category News Views 95

Friday’s radar and communications trouble delivered the sort of warning nobody in aviation can shrug off: the machinery behind the flight board is getting old, fragile, and far too dependent on people improvising around it. Thousands of flights were delayed or canceled when air traffic control facilities became unstable, according to the Southwest Airlines Pilots...

Continue Reading
Fervo’s 46% Slide Puts Geothermal Claims Under Fire

Updated Category News Views 162

A 46% haircut from an IPO price has a way of stripping the paint off a growth story. Fervo Energy closed at $14.33 after the October 6 report cited in Hagens Berman’s announcement, well below its $27 IPO price from last May. That does not prove the report is right. It does mean NASDAQ:FRVO investors are staring at questions that go straight to the economic spine of...

Continue Reading
Automus and Google Cloud Put Agents to Work on Oracle

Updated Category News Views 68

Oracle back offices are where shiny AI promises go to earn their keep, or get buried under a mountain of integrations. Automus Consulting’s newly announced collaboration with Google Cloud, unveiled November 20 at Oracle AI World, is aimed squarely at that messy middle. The firm wants to combine its Oracle implementation experience with Google Cloud infrastructure and...

Continue Reading
MemorialCare Adds AI Guardrails for Hidden Aneurysms

Updated Category News Views 141

A brain scan ordered for one reason can suddenly expose a risk nobody knew was sitting there. That is the sober promise behind MemorialCare Neuroscience Institute's rollout of Rapid Aneurysm, an artificial-intelligence tool embedded in qualifying CTA and MRA brain scans across its inpatient and outpatient network. MemorialCare says it is the first health system in Los...

Continue Reading
Zesty Takes Kubernetes Cost Control Into GPU Territory

Updated Category News Views 88

GPU waste has become the sort of cloud bill nobody wants to explain upstairs. A company buys scarce, expensive accelerators for AI work, then discovers that real workloads do not politely consume resources in neat, permanent blocks. Demand jumps, memory needs shift, and somebody either over-allocates to avoid trouble or under-allocates and gets ugly out-of-memory...

Continue Reading
Chicago Kertész Show Puts Photography's Quiet Giant First

Updated Category News Views 49

A fork, a plate, and a sharp eye can outlast plenty of louder art. Leica Gallery Chicago is putting that proposition on the wall with André Kertész: The Master, opening December 4, 2026 and running through January 17, 2027. More than thirty signature works is not a sprawling museum survey, and frankly that may be the point. Kertész did not need grand scale to make his...

Continue Reading

Top 5 Most Recently Viewed Articles

BingX Enhances Trading Experience with CScalp Integration

Updated Category News Views 197

BingX Introduces Enhanced Trading Features with CScalp BingX, a prominent name in the cryptocurrency exchange sphere, has recently announced its integration with CScalp, a powerful trading terminal designed for both cryptocurrency and futures traders. This collaboration aims to provide users with cutting-edge trading tools, significantly enhancing their overall trading...

Continue Reading
Moscow Stocks Decline: Insights into Market Performance

Updated Category News Views 106

Moscow Stocks Face a Decline In the latest trading sessions, Moscow stocks have shown a clear downturn, with certain sectors especially driving this trend. The shifting dynamics within these sectors have created a challenging environment for investors. Performance by Sector and Important Takeaways The Telecoms, Mining, and Power sectors have been particularly tough,...

Continue Reading
Innovative Collaboration between Precision for Medicine and PathAI

Updated Category News Views 389

Strategic Alliance for Advancing Clinical Trials In a groundbreaking announcement, Precision for Medicine and PathAI are collaborating to revolutionize clinical trials and biomarker discovery. This partnership is set to introduce the next generation of AI-powered pathology tools designed to enhance quality control in clinical research. Enhancing Clinical Research...

Continue Reading
Declining Brazil Orange Juice Exports: Key Insights & Trends

Updated Category News Views 279

Overview of Brazil's Orange Juice Export Decline Brazil's orange juice exports have faced a significant downturn, with a 19.7% decrease in the first half of the 2024/25 crop season compared to the same time last year, as reported by CitrusBR. This decline represents approximately 535,600 metric tons of juice exports during this period, according to industry data....

Continue Reading
Celebrating 25 Years of Innovation in Legal Marketing

Updated Category News Views 164

Celebrating Two and a Half Decades of Digital Marketing PaperStreet Web Design, a pioneer in legal marketing, proudly marks its 25th anniversary. Founded by attorney and visionary Peter Boyd in 2001, this agency began as a one-person endeavor and has evolved into a nationally recognized firm employing over 30 professionals. With a rich history of aiding more than 2,500...

Continue Reading